A Rare Cutaneous Manifestation: Leukocytoclastic Vasculitis after Pfizer-BioNTech COVID-19 Vaccination
There is growing evidence that vaccines against SARS-CoV-2 can cause various skin reactions, many of which have autoimmune origins. These specific vaccine-induced autoimmune conditions with cutaneous manifestations include lupus erythematosus, bullous pemphigoid, vitiligo, alopecia areata, and leuko...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-01-01
|
| Series: | Case Reports in Dermatological Medicine |
| Online Access: | http://dx.doi.org/10.1155/2022/4267930 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832552739845963776 |
|---|---|
| author | Yaritza Serrano Gomez Brittney Grella Hongbei Wang |
| author_facet | Yaritza Serrano Gomez Brittney Grella Hongbei Wang |
| author_sort | Yaritza Serrano Gomez |
| collection | DOAJ |
| description | There is growing evidence that vaccines against SARS-CoV-2 can cause various skin reactions, many of which have autoimmune origins. These specific vaccine-induced autoimmune conditions with cutaneous manifestations include lupus erythematosus, bullous pemphigoid, vitiligo, alopecia areata, and leukocytoclastic vasculitis (LCV). In particular, LCV, which is also called hypersensitivity vasculitis, is an inflammation of small blood vessels. We present a case of an 81-year-old male evaluated in the emergency department for a bilateral purpuric non-blanching rash that appeared ten days after receiving the Pfizer-BioNTech booster vaccine against SARS-CoV-2. Results of a skin biopsy indicated LCV, and the rash completely resolved three weeks after clinical presentation. |
| format | Article |
| id | doaj-art-ca5c24ea31fd4cda95862dc3e94506cf |
| institution | Kabale University |
| issn | 2090-6471 |
| language | English |
| publishDate | 2022-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Dermatological Medicine |
| spelling | doaj-art-ca5c24ea31fd4cda95862dc3e94506cf2025-02-03T05:57:56ZengWileyCase Reports in Dermatological Medicine2090-64712022-01-01202210.1155/2022/4267930A Rare Cutaneous Manifestation: Leukocytoclastic Vasculitis after Pfizer-BioNTech COVID-19 VaccinationYaritza Serrano Gomez0Brittney Grella1Hongbei Wang2Department of Family MedicineDepartment of MedicineDepartment of PathologyThere is growing evidence that vaccines against SARS-CoV-2 can cause various skin reactions, many of which have autoimmune origins. These specific vaccine-induced autoimmune conditions with cutaneous manifestations include lupus erythematosus, bullous pemphigoid, vitiligo, alopecia areata, and leukocytoclastic vasculitis (LCV). In particular, LCV, which is also called hypersensitivity vasculitis, is an inflammation of small blood vessels. We present a case of an 81-year-old male evaluated in the emergency department for a bilateral purpuric non-blanching rash that appeared ten days after receiving the Pfizer-BioNTech booster vaccine against SARS-CoV-2. Results of a skin biopsy indicated LCV, and the rash completely resolved three weeks after clinical presentation.http://dx.doi.org/10.1155/2022/4267930 |
| spellingShingle | Yaritza Serrano Gomez Brittney Grella Hongbei Wang A Rare Cutaneous Manifestation: Leukocytoclastic Vasculitis after Pfizer-BioNTech COVID-19 Vaccination Case Reports in Dermatological Medicine |
| title | A Rare Cutaneous Manifestation: Leukocytoclastic Vasculitis after Pfizer-BioNTech COVID-19 Vaccination |
| title_full | A Rare Cutaneous Manifestation: Leukocytoclastic Vasculitis after Pfizer-BioNTech COVID-19 Vaccination |
| title_fullStr | A Rare Cutaneous Manifestation: Leukocytoclastic Vasculitis after Pfizer-BioNTech COVID-19 Vaccination |
| title_full_unstemmed | A Rare Cutaneous Manifestation: Leukocytoclastic Vasculitis after Pfizer-BioNTech COVID-19 Vaccination |
| title_short | A Rare Cutaneous Manifestation: Leukocytoclastic Vasculitis after Pfizer-BioNTech COVID-19 Vaccination |
| title_sort | rare cutaneous manifestation leukocytoclastic vasculitis after pfizer biontech covid 19 vaccination |
| url | http://dx.doi.org/10.1155/2022/4267930 |
| work_keys_str_mv | AT yaritzaserranogomez ararecutaneousmanifestationleukocytoclasticvasculitisafterpfizerbiontechcovid19vaccination AT brittneygrella ararecutaneousmanifestationleukocytoclasticvasculitisafterpfizerbiontechcovid19vaccination AT hongbeiwang ararecutaneousmanifestationleukocytoclasticvasculitisafterpfizerbiontechcovid19vaccination AT yaritzaserranogomez rarecutaneousmanifestationleukocytoclasticvasculitisafterpfizerbiontechcovid19vaccination AT brittneygrella rarecutaneousmanifestationleukocytoclasticvasculitisafterpfizerbiontechcovid19vaccination AT hongbeiwang rarecutaneousmanifestationleukocytoclasticvasculitisafterpfizerbiontechcovid19vaccination |